How Should Nursing Homes Use Vaccine to Prevent Zoster?

Journal of the American Medical Directors Association

Volumn 8, Issue 7, 2007, Pages 419-420

  Drinka, Paul J ^a  

^a Wisconsin Department of Veterans Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; PLACEBO; VARICELLA ZOSTER VACCINE;

CLINICAL TRIAL; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG LABELING; DRUG RESPONSE; EDITORIAL; HERPES ZOSTER; HUMAN; NURSING HOME; NURSING HOME PATIENT; PATHOPHYSIOLOGY; PREVALENCE; VACCINATION;

EID: 34548411670     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2007.06.001     Document Type: Editorial

References (11)

1. Oxman M.N., Levin M.J., Johnson G.R., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005) 2271-2284
2. Advisory Committee on Immunization Practices (ACIP). ACIP Provisional recommendations for the use of zoster vaccine (2006). http://www.cdc.gov/nip/recs/provisional_recs/zoster-11-20-06.pdf Nov. 20, prepublication issue available at: www.cdc.gov/nip/recs/provisional_recs/zoster-11-20-06.pdf. Accessed April 24, 2007. MMWR Morb Mortal Wkly Rep, June 2007. In press.
3. Donahue J.G., Choo P.W., Manson J.E., and Platt R. The incidence of herpes zoster. Arch Int Med 155 (1995) 1605-1609
4. Kost R.G., and Straus S.E. Postherpetic neuralgia-pathogenesis, treatment, and prevention. N Engl J Med 335 (1996) 32-42
5. Ragozzino M.W., Melton III L.J., Kurland L.T., Chu C.P., and Perry H.O. Population-based study of herpes zoster and its sequelae. Medicine 61 (1982) 310-316
6. Consult 2007 PDR. Zostavax [Zoster Vaccine Live (Oka/Merck) package insert]. Whitehouse Station (NJ): Merck & Co., Inc., May, 2006, pp. 2111-2114.
7. Levin M.J. Herpes zoster vaccine. In: Plotkin S.A. (Ed). Vaccines-Continuing Medical Education Update (2007), Elsevier Office of CME, Bridgewater (NJ) 1-10 January
8. Hornberger J., and Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 145 (2006) 317-325
9. Rothberg M.B., Virapongse A., and Smith K.J. Cost-effectiveness of a vaccine to prevent zoster and postherpetic neuralgia in older adults. Clin Infect Dis 44 (2007) 1280-1288
10. Merck. Zoster vaccine line (Oka/Merck) Zostavax. FDA clinical briefing document for Merck and Co., 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/5-4198B2_1.pdf. Accessed May 10, 2007.
11. Kimberlin D.W., and Whitley R.J. Varicella-Zoster vaccine for the prevention of herpes zoster. N Engl J Med 356 (2007) 1338-1343